Summary: Cortechs.ai is expanding into the urologic oncology market with OnQ Prostate, an FDA-cleared MRI software for detecting prostate cancer, while also releasing NeuroQuant v5.0 for identifying cerebral microhemorrhages in brain conditions.

Key Takeaways:

  1. Cortechs.ai is expanding into the urologic oncology market with OnQ Prostate, an FDA-cleared prostate MRI solution.
  2. OnQ Prostate uses Restriction Spectrum Imaging to improve the detection and specificity of aggressive cancer cells.
  3. The software enhances MR-based cancer detection and correlates better with histopathology compared to conventional imaging.

———————————————————————————————————————————————————————

Cortechs.ai is expanding into the urologic oncology market with OnQ Prostate, a prostate MRI solution. OnQ Prostate is FDA-cleared post-processing software that aids radiologists in detecting clinically significant prostate cancer using Restriction Spectrum Imaging (RSI). RSI improves the detection and specificity of aggressive cancer cells. Studies have shown that RSI enhances MR-based cancer detection and correlates better with histopathology compared to conventional imaging.

Initially used by select academic institutions and imaging centers, OnQ Prostate is now available for broader commercialization. Brittany Hunt, head of prostate business development at Cortechs.ai, states that this expansion aims to increase the accessibility of OnQ Prostate.

OnQ Prostate offers improved PI-RADS accuracy, inter-reader agreement, and workflow efficiency. It also facilitates non-radiologists in interpreting and using the images, aiding urologists in biopsy and treatment planning and simplifying communication with patients. The software enhances clinical workflows throughout the prostate cancer care pathway.

In related news, Cortechs.ai has released NeuroQuant v5.0, which identifies and evaluates cerebral microhemorrhages on susceptibility-sensitive MRI sequences. This update is intended for patients with brain conditions such as traumatic brain injuries, cerebral amyloid angiopathy, Alzheimer’s disease, and amyloid related imaging abnormalities.